ACP3 and posterior cortical atrophy: More recent innovations in PCa treatment include the autologous immunotherapy Sipuleucel-T (approved in the USA), which uses a patient's own antigen-presenting cells activated by prostatic acid phosphatase (PAP) which, in turn, stimulates a T cell immune response to PCa cells [40].